Biotech News

Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman

Annovis Bio (ANVS)Annovis BioFinancing

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that its Chairman participated in the underwritten public offering and contributed $5.00 million, or approximately 24% of the $21.0 million offering, which closed on November 6, 2026.

Related news

ANVSAnnovis Bio2026-11-05 13:05 EST

Annovis Announces Pricing of $21.0 Million Public Offering

ANVSAnnovis Bio2026-11-04 21:07 EST

Annovis Announces Launch of Proposed Public Offering

CLNNClene Inc.2026-09-15 13:00 EST

Clene Announces $4 Million Registered Direct Offering

CLNNClene Inc.2026-09-21 12:30 EST

Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA

PRAXPraxis Precision Medicines2026-11-12 21:30 EST

Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day

SUPNSupernus2026-11-10 13:30 EST

Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London

ABOSAcumen Pharmaceuticals2026-10-30 11:00 EST

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

ANNXAnnexon, Inc.2026-10-28 12:01 EST

Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

ECORelectroCore2026-10-28 12:00 EST

electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Annovis Bio

Phase 3 Neurodegenerative Disease Company Annovis Bio is developing buntanetap, an oral candidate for Alzheimer’s disease and Parkinson’s disease. Through an RNA-targeting mechanism, buntanetap is designed to reduce translation of multiple neurotoxic proteins, including APP/amyloid beta, tau, alpha-synuclein, and TDP-43. Registrational...

Recent company news

Stock data

Close
0.75 USD
Market cap
79.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States